Real-time · AI · Cross-signal

Jurgen Van Broeck just moved. Here's exactly what to do next.

Who to reach, what to say, and why now — on Jurgen Van Broeck's next role move, new team, and the deals that follow. Verified, ICP-ranked contacts on demand (email + mobile).

Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.

Choose your plan Request a demo

Everyone else gives you a piece

✕Crunchbase & PitchBook list the company — No person, no timing, no opener.

✕ZoomInfo & Apollo sell you a contact — No trigger, no reason to reach out now.

✕LinkedIn Sales Navigator shows you people — No real-time signal, no opener.

✕Clay enriches lists you built — No live signal of its own, no who or when.

✕ChatGPT & gen-AI tools answer on a delay — No live data, no verified contact.

Who to contactWhat to sayWhen to reach outWhy now

Only Fundz delivers all four.

M Abxience Appoints Jurgen Van Broeck As Chief Executive Officer

PRIVATEMay 09, 2024•about 2 years ago

Position

Chief Executive Officer

Company

mAbxience

Jurgen Van Broeck

MadridBiotechnology

Description

mAbxience is pleased to announce the appointment of Jurgen Van Broeck as Chief Executive Officer. Jurgen, who has served as Global Commercial Director since June 2023, brings a great deal of experience and a proven track record in the pharmaceutical and biosimilars industries.

Company Information

Company

mAbxience

Location

Madrid, Community Of Madrid, Spain

About

mAbxience is a Spanish-based company specializing in the development, production, and commercialization of biopharmaceuticals. With over a decade of expertise, our mission is clear: to provide accessible, affordable medicines across the globe, aiming to enhance the quality of life by ensuring universal access to high-caliber medicines. With two market-approved products and a robust pipeline in development, we have established a B2B presence in over 100 markets. Alongside this, we have formed a network with more than 30 partners and built a dedicated team of over 1,000 professionals. Our three multi-product facilities, located in Europe and South America, have obtained GMP approval from esteemed regulatory bodies, including the FDA, EMA, and others. Furthermore, as a global biopharmaceutical expert, mAbxience specializes in Contract Development and Manufacturing Organization services (CDMO), utilizing advanced technology and innovative platforms to deliver integrated manufacturing solutions. For more insights into mAbxience, our biosimilars and CDMO business, please visit our website (www.mabxience.com)

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for mAbxience's next move

Learn about Strategic plan

Executive Insights

Based on hiring data

New executive impact window

87% of new executives make significant technology decisions within first 100 days

Budget influence

C-level executives control 73% of technology spending decisions

Transformation catalyst

65% of new senior hires launch digital transformation initiatives

Vendor review timeline

New executives typically review existing vendors within 6 months